Evidence map›Paper›PMID 31848605›Full record

ArticleJournal of the National Cancer Institute2020

Breast Cancer Mortality After Implementation of Organized Population-Based Breast Cancer Screening in Norway.

Sofie Sebuødegård, Edoardo Botteri, Solveig Hofvind

Erratum issuedAbstract readHistorical Article
PubMed Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  11. The Role of the 21-Gene Recurrence ScoreCurrent oncology (Toronto, Ont.) · 2022
    Review
  12. Review
  13. Review
  14. Response to Zahl.Journal of the National Cancer Institute · 2020
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Sofie SebuødegårdSection for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
Edoardo BotteriSection for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
Solveig HofvindFaculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe estimated breast cancer (BC) mortality reduction associated with invitations to a nationwide population-based screening program and with changes in treatment. MATERIALS AND

methodsBreastScreen Norway started in 1996 and became nationwide in 2005. It invites women aged 50-69 years to biennial mammographic screening. We retrieved individual-level data for 1 340 333 women from national registries. During 1996-2014 (screening window), women contributed person-years in noninvited and invited periods. We created comparable periods for 1977-1995 (prescreening window) by dividing the follow-up time for each woman into pseudo-noninvited and pseudo-invited periods. We estimated BC mortality for the four periods, using the so-called evaluation model: counting BC deaths in each period for all women diagnosed within the period and counting BC deaths and person-years after screening-age for those diagnosed within screening age. We used a multivariable flexible parametric survival model to estimate hazard ratio (HR) for the effect of invitation and improved treatment.

resultsUsing the regression approach, we found 5818 BC deaths across 16 533 281 person-years. Invitations to screening reduced BC mortality by 20% (HR = 0.80, 95% confidence interval [CI] = 0.70 to 0.91) among women 50 years and older and by 25% (HR = 0.75, 95% CI = 0.65 to 0.86) among screening-aged women. The treatment effect was 23% (HR = 0.77, 95% CI = 0.65 to 0.92) for women 50 years and older and 17% (HR = 0.83, 95% CI = 0.74 to 0.94) for screening-aged women.

conclusionWe observed a similar reduction in BC mortality associated with invitations to screening and improvements in treatment during 1977-2014, among women 50 years and older.

Indexed as

Early Detection of CancerHealth Plan ImplementationMass ScreeningAgedBreast NeoplasmsEfficiency, OrganizationalFemaleHistory, 20th CenturyHistory, 21st CenturyHumansImplementation ScienceMammographyMiddle AgedMortalityNorwayRegistries

Identifiers

PMID31848605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.